Works matching IS 00126667 AND DT 2022 AND VI 82 AND IP 15

Results: 6
    1
    2
    3

    Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.

    Published in:
    Drugs, 2022, v. 82, n. 15, p. 1527, doi. 10.1007/s40265-022-01797-x
    By:
    • Khanna, Sahil;
    • Assi, Maha;
    • Lee, Christine;
    • Yoho, David;
    • Louie, Thomas;
    • Knapple, Whitfield;
    • Aguilar, Humberto;
    • Garcia-Diaz, Julia;
    • Wang, Gary P.;
    • Berry, Scott M.;
    • Marion, Joe;
    • Su, Xin;
    • Braun, Tricia;
    • Bancke, Lindy;
    • Feuerstadt, Paul
    Publication type:
    Article
    4
    5
    6

    Pucotenlimab: First Approval.

    Published in:
    Drugs, 2022, v. 82, n. 15, p. 1557, doi. 10.1007/s40265-022-01787-z
    By:
    • Dhillon, Sohita
    Publication type:
    Article